USAID is offering the Innovations in Malaria Vaccine Development Grant to support collaborative efforts in designing a vaccine with at least 75% efficacy against Plasmodium falciparum malaria. The grant aims to reduce morbidity and mortality by targeting the pre-erythrocytic and erythrocytic stages of the malaria life cycle. Expressions of Interest are sought for novel approaches spanning preclinical to proof of principle clinical studies, to advance the development of an effective malaria vaccine. Deadline for submissions is June 21, 2019.
Opportunity ID: 316074
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | GH-BAA-2018-ADDENDUM03 |
| Funding Opportunity Title: | Innovations in Malaria Vaccine Development (IMV) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Other |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 98.001 — USAID Foreign Assistance for Programs Overseas |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 17, 2019 |
| Last Updated Date: | May 17, 2019 |
| Original Closing Date for Applications: | Jun 21, 2019 |
| Current Closing Date for Applications: | Jun 21, 2019 |
| Archive Date: | Jul 21, 2019 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $35,500,000 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Agency for International Development |
| Description: | USAID is seeking to enhance our malaria vaccine investments through a collaborative design process. The goal of USAID’s Malaria Vaccine Development Program (MVDP) is to demonstrate the proof of concept of a vaccine to reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. Target malaria vaccine end characteristics will include at least 75% efficacy and evidence of affordability. USAID intends to support efforts towards vaccines that have the potential to directly protect recipients against disease caused by P. falciparum such as vaccines that target the pre-erythrocytic (sporozoite and liver stage) and erythrocytic stages of the life cycle. The purpose of this Addendum is to solicit Expressions of Interest (EOI) for novel and innovative approaches to malaria vaccine development that would encompass preclinical development through proof of principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Christie Cooper
Contract Specialist Email:ghmvdpbaa@usaid.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 316074 Full Announcement-GH-BAA-2018-Addendum03 -> GH-BAA-2018-Addendum03.pdf
Folder 316074 Other Supporting Documents-GH-BAA-2018-Addendum03-Amend1 -> GH-BAA-2018-Addendum03.Amendment1.pdf
Packages
There are no packages on this grant.
Share This Post, Choose Your Platform!
About the Author: osnqt
